Altimmune announce results from analysis of biopsies from IMPACT Phase 2b trial

Altimmune (ALT) announced results from an artificial intelligence-based analysis of biopsies from the IMPACT Phase 2b trial of pemvidutide in patients with metabolic dysfunction-associated steatohepatitis. Highlights from the AI-based analysis of biopsies from patients in the IMPACT Phase 2b trial include: Data for total fibrosis showed 31% of patients in the pemvidutide 1.8 mg group (n = 85), and 12% of patients in the pemvidutide 1.2 mg group achieved a greater than or equal to 60% reduction in the area of fibrosis compared to 8% of placebo-treated patients. Data for early fibrosis showed 34% of patients in the pemvidutide 1.8 mg group, and 24% of patients in the pemvidutide 1.2 mg group achieved greater than or equal to 60% reduction in the area of fibrosis compared to 9% of placebo-treated patients. Data for advanced fibrosis showed 27% of patients in the pemvidutide 1.8 mg group, and 5% of patients in the pemvidutide 1.2 mg group achieved greater than or equal to 60% reduction in the area of fibrosis compared to 11% of placebo-treated patients.